Immunological pathways in viral hepatitis-induced hepato-cellular carcinoma.

肝炎病毒感染导致肝细胞癌发生的免疫机制研究进展.

Journal

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
ISSN: 1008-9292
Titre abrégé: Zhejiang Da Xue Xue Bao Yi Xue Ban
Pays: China
ID NLM: 100927946

Informations de publication

Date de publication:
19 Jan 2024
Historique:
medline: 4 3 2024
pubmed: 1 3 2024
entrez: 1 3 2024
Statut: epublish

Résumé

Hepatocellular carcinoma (HCC) is a serious neoplastic disease with increasing incidence and mortality, accounting for 90% of all liver cancers. Hepatitis viruses are the major causative agents in the development of HCC. Hepatitis A virus (HAV) primarily causes acute infections, which is associated with HCC to a certain extent, as shown by clinicopathological studies. Chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infections lead to persistent liver inflammation and cirrhosis, disrupt multiple pathways associated with cellular apoptosis and proliferation, and are the most common viral precursors of HCC. Mutations in the HBV X protein (HBx) gene are closely associated with the incidence of HCC, while the expression of HCV core proteins contributes to hepatocellular lipid accumulation, thereby promoting tumorigenesis. In the clinical setting, hepatitis D virus (HDV) frequently co-infects with HBV, increasing the risk of chronic hepatitis. Hepatitis E virus (HEV) usually causes acute infections. However, chronic infections of HEV have been increasing recently, particularly in immuno-compromised patients and organ transplant recipients, which may increase the risk of progression to cirrhosis and the occurrence of HCC. Early detection, effective intervention and vaccination against these viruses may significantly reduce the incidence of liver cancer, while mechanistic insights into the interplay between hepatitis viruses and HCC may facilitate the development of more effective intervention strategies. This article provides a comprehensive overview of hepatitis viruses and reviews recent advances in research on aberrant hepatic immune responses and the pathogenesis of HCC due to viral infection. 肝炎病毒感染是肝细胞癌的主要致病因素之一。甲型肝炎病毒(HAV)通常引起急性感染,临床病理长期追踪结果显示HAV感染与肝细胞癌发生有一定联系。乙型肝炎病毒(HBV)或丙型肝炎病毒(HCV)的慢性感染可导致长期肝脏炎症和肝硬化,影响多条细胞凋亡和增殖相关信号通路,是病毒感染导致肝细胞癌的最常见诱因。HBV X蛋白(HBx)基因突变与肝细胞癌发病率密切相关,HCV核心蛋白的表达可导致肝细胞脂质积累,促进肿瘤发生。临床丁型肝炎病毒(HDV)感染常伴随HBV的共感染,从而增加慢性肝炎风险。戊型肝炎病毒(HEV)感染通常呈急性,近年HEV在器官移植和免疫缺陷患者中慢性感染增多。HEV慢性感染易导致肝硬化而增加肝细胞癌风险。本文概述了近年来肝炎病毒感染导致肝脏免疫应答异常和肝细胞癌发生的研究进展,以期有助于寻找病毒感染的早期检测、有效干预和疫苗接种的措施。.

Autres résumés

Type: Publisher (chi)
肝炎病毒感染是肝细胞癌的主要致病因素之一。甲型肝炎病毒(HAV)通常引起急性感染,临床病理长期追踪结果显示HAV感染与肝细胞癌发生有一定联系。乙型肝炎病毒(HBV)或丙型肝炎病毒(HCV)的慢性感染可导致长期肝脏炎症和肝硬化,影响多条细胞凋亡和增殖相关信号通路,是病毒感染导致肝细胞癌的最常见诱因。HBV X蛋白(HBx)基因突变与肝细胞癌发病率密切相关,HCV核心蛋白的表达可导致肝细胞脂质积累,促进肿瘤发生。临床丁型肝炎病毒(HDV)感染常伴随HBV的共感染,从而增加慢性肝炎风险。戊型肝炎病毒(HEV)感染通常呈急性,近年HEV在器官移植和免疫缺陷患者中慢性感染增多。HEV慢性感染易导致肝硬化而增加肝细胞癌风险。本文概述了近年来肝炎病毒感染导致肝脏免疫应答异常和肝细胞癌发生的研究进展,以期有助于寻找病毒感染的早期检测、有效干预和疫苗接种的措施。.

Identifiants

pubmed: 38426692
doi: 10.3724/zdxbyxb-2023-0481
doi:

Types de publication

Review Journal Article

Langues

eng chi

Sous-ensembles de citation

IM

Pagination

64-72

Références

Hepatology. 2007 Jan;45(1):42-52
pubmed: 17187432
Nature. 2013 Apr 18;496(7445):367-71
pubmed: 23542590
Biochim Biophys Acta. 2001 Feb 5;1538(1):59-66
pubmed: 11341983
J Hepatobiliary Pancreat Surg. 2004;11(3):215-9
pubmed: 15235898
Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2230-4
pubmed: 8134379
Cells. 2019 Nov 11;8(11):
pubmed: 31718044
J Gen Virol. 2015 Sep;96(9):2670-2683
pubmed: 26296767
J Gastroenterol Hepatol. 1997 Oct;12(9-10):S188-92
pubmed: 9407337
Gut. 2007 Feb;56(2):304
pubmed: 17303607
Nature. 1993 Feb 25;361(6414):742-5
pubmed: 8441471
Viruses. 2020 Jun 16;12(6):
pubmed: 32560053
Hepatology. 2002 Nov;36(5):1206-13
pubmed: 12395331
Arch Immunol Ther Exp (Warsz). 2002;50(5):307-16
pubmed: 12455864
Viruses. 2021 May 08;13(5):
pubmed: 34066709
Int J Cancer. 2022 Jun 1;150(11):1825-1837
pubmed: 35020946
Front Cell Infect Microbiol. 2023 May 17;13:1189417
pubmed: 37265499
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
J Viral Hepat. 1997 Jul;4(4):279-83
pubmed: 9278226
Oncogene. 2008 Oct 20;27(48):6228-44
pubmed: 18931690
Nat Rev Dis Primers. 2018 Jun 07;4:18035
pubmed: 29877316
Nat Rev Gastroenterol Hepatol. 2010 Jan;7(1):31-40
pubmed: 20051970
Cancer Biol Med. 2014 Sep;11(3):182-90
pubmed: 25364579
J Clin Oncol. 2013 Oct 10;31(29):3647-55
pubmed: 24002499
Int J Epidemiol. 1980 Sep;9(3):221-3
pubmed: 6254892
Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50
pubmed: 15508101
Cell Mol Gastroenterol Hepatol. 2017 Oct 16;5(2):101-112
pubmed: 29693039
Hepatol Res. 2008 Jan;38(1):1-26
pubmed: 17894800
J Gen Virol. 2002 Sep;83(Pt 9):2145-2151
pubmed: 12185267
Hum Mutat. 2003 Mar;21(3):201-16
pubmed: 12619106
Cold Spring Harb Perspect Med. 2015 Jul 01;5(7):a021576
pubmed: 26134842
Biochem Biophys Res Commun. 2000 Feb 16;268(2):456-61
pubmed: 10679226
Arch Virol. 2004 Feb;149(2):323-36
pubmed: 14745598
Oncotarget. 2016 Aug 30;7(35):56107-56119
pubmed: 27528231
J Hepatol. 2022 Dec;77(6):1598-1606
pubmed: 36208844
J Hepatol. 2016 Apr;64(1 Suppl):S84-S101
pubmed: 27084040
J Oncol. 2021 Dec 10;2021:5905357
pubmed: 34925509
JAMA. 2000 Jul 26;284(4):450-6
pubmed: 10904508
Biochem Biophys Res Commun. 2002 Jun 14;294(3):528-34
pubmed: 12056798
Hepatology. 1997 Sep;26(3 Suppl 1):15S-20S
pubmed: 9305658
RNA Biol. 2011 Mar-Apr;8(2):258-69
pubmed: 21593584
Antivir Ther. 1998;3(Suppl 3):37-42
pubmed: 10726054
Clin Immunol. 2010 Mar;134(3):237-50
pubmed: 19910258
DNA Cell Biol. 2017 Aug;36(8):693-708
pubmed: 28598207
Expert Opin Biol Ther. 2010 Nov;10(11):1563-72
pubmed: 20932226
Nat Genet. 2012 May 27;44(7):765-9
pubmed: 22634754
Viruses. 2016 Aug 15;8(8):
pubmed: 27537905
Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17717-22
pubmed: 16301520
Cancer Epidemiol. 2023 Dec;87:102457
pubmed: 37797398
Hepatol Int. 2017 Nov;11(6):500-508
pubmed: 29098564
J Exp Med. 2002 Jan 7;195(1):43-9
pubmed: 11781364
Pathogens. 2024 Jan 10;13(1):
pubmed: 38251375
Science. 1991 Jul 5;253(5015):49-53
pubmed: 1905840
Nat Rev Immunol. 2016 Aug;16(8):509-23
pubmed: 27374637
Cureus. 2020 Oct 30;12(10):e11269
pubmed: 33274145
Nat Rev Cancer. 2013 Feb;13(2):123-35
pubmed: 23344543
Dig Liver Dis. 2021 Mar;53(3):360-366
pubmed: 33153927
Alcohol Clin Exp Res. 2010 Oct;34(10):1675-86
pubmed: 20608905
Hepatology. 2013 Apr;57(4):1333-42
pubmed: 23172780
Expert Rev Anti Infect Ther. 2011 Dec;9(12):1133-48
pubmed: 22114964
Cold Spring Harb Perspect Med. 2019 Jan 2;9(1):
pubmed: 29661811
Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):9555-60
pubmed: 24941955
Clin Cancer Res. 2019 Sep 15;25(18):5525-5536
pubmed: 31152021
Front Immunol. 2021 Nov 22;12:768098
pubmed: 34880864
Nat Rev Immunol. 2005 Mar;5(3):215-29
pubmed: 15738952
Science. 1989 Apr 21;244(4902):359-62
pubmed: 2523562
J Hepatol. 2021 Apr;74(4):952-963
pubmed: 33276027
Oncogene. 2004 Oct 14;23(47):7821-38
pubmed: 15334054
Curr Oncol. 2016 Feb;23(1):e49-56
pubmed: 26966413
J Hepatol. 2012 Mar;56(3):704-13
pubmed: 22120206
Hepatology. 2006 Jun;43(6):1317-25
pubmed: 16729309

Auteurs

Lingdong Xu (L)

Laboratory Animal Center, Zhejiang University, Hangzhou 310058, China. xulingdong@zju.edu.cn.
Zhejiang University School of Medicine, Hangzhou 310058, China. xulingdong@zju.edu.cn.

Yifan Xu (Y)

Life Sciences Institute, Zhejiang University, Hangzhou 310058, China.

Fei Zhang (F)

Life Sciences Institute, Zhejiang University, Hangzhou 310058, China.
Institute of Intelligent Medicine, Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou 311200, China.

Pinglong Xu (P)

Life Sciences Institute, Zhejiang University, Hangzhou 310058, China. xupl@zju.edu.cn.
Institute of Intelligent Medicine, Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou 311200, China. xupl@zju.edu.cn.
Key Laboratory of Biosystems Homeostasis and Protection, Ministry of Education, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Zhejiang University, Hangzhou 310058, China. xupl@zju.edu.cn.
Cancer Center, Zhejiang University, Hangzhou 310058, China. xupl@zju.edu.cn.

Lie Wang (L)

Laboratory Animal Center, Zhejiang University, Hangzhou 310058, China. wanglie@zju.edu.cn.
Zhejiang University School of Medicine, Hangzhou 310058, China. wanglie@zju.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH